Platelet Antigen Genotyping Panel
Platelets play a critical role in blood clotting and hemostasis. These cells express various proteins on their membranes, including receptors for complement, chemokines, and adhesion molecules. Human Platelet Antigens (HPA) are a group of proteins expressed on platelet membranes, including glycoproteins such as GPIIb, GPIIIa, GPIa, GPIbα, GPIbβ, and CD36. HPAs are classified into seven biallelic systems: HPA-1 to -6 and HPA-15. Most HPAs are located on integrin αIIbβ3 (the fibrinogen receptor), and their variations are often nonsynonymous single nucleotide polymorphisms (SNPs). Differences in HPA expression between individuals may trigger immune responses, leading to antibody production. These antibodies can cause alloimmune thrombocytopenia, leading to conditions such as:
- Neonatal Alloimmune Thrombocytopenia (NAIT): Occurs when maternal antibodies attack fetal platelets.
- Platelet Transfusion Refractoriness (PTR): A reduced response to platelet transfusions.
- Post-Transfusion Purpura (PTP): A rare but severe condition following platelet transfusion.
The HPA genotyping panel screens for variations in six genes: ITGB3, GP1BA, ITGA2B, ITGA2, and CD109. This testing has two primary clinical applications:
- HPA Typing for Transfusion Matching: To prevent alloimmune reactions such as PTR and PTP, HPA typing helps match platelet donors to recipients with prior transfusions or those who have developed anti-HPA antibodies.
- Diagnosis of Hereditary Platelet Disorders: HPA genotyping assists in diagnosing hereditary platelet disorders when phenotypic assays are inconclusive.
- Fetal or neonatal evaluation when unexplained intracranial hemorrhage (ICH) or thrombocytopenia is detected, findings that raise suspicion for neonatal alloimmune thrombocytopenia (NAIT), also known as perinatal alloimmune thrombocytopenia (PAT).
- Testing of both maternal and paternal samples is recommended when NAIT is suspected in the fetus or neonate to assess HPA incompatibility.
- Women with a history of a previously affected pregnancy, posttransfusion purpura, or a sister who has had an affected pregnancy are considered candidates for HPA genotyping to evaluate potential alloimmune risk in future pregnancies.
Additionally, research indicates that HPA polymorphisms may play a role in various pathologies, such as: cancer metastasis (e.g., melanoma, lung cancer), ischemic stroke, enhanced viral and bacterial virulence. However, these associations are still under investigation.
- Fetal or neonatal evaluation when unexplained intracranial hemorrhage (ICH) or thrombocytopenia
- Aids in selecting donors for patients with Human Platelet Antigens alloantibodies
- Prevents PTR and PTP through pre-transfusion Human Platelet Antigens matching
- Assesses the risk of neonatal alloimmune thrombocytopenia (NAIT)
HPA a/a homozygous: Two copies of the common 'a' allele.
HPA a/b heterozygous: One copy of the common 'a' allele and one copy of the less common 'b' allele.
HPA b/b homozygous: Two copies of the less common 'b' allele.
No established reference ranges
Whole Blood (EDTA), Amniotic Fluid.
Stability
Whole Blood:
- Ambient: 3–5 days.
- Refrigerated: 7–14 days.
- Frozen: Unacceptable.
Amniotic Fluid
- Ambient: 48 hours.
- Refrigerated or frozen: Unacceptable
- Transfusion. 2011 Mar; 51(3):558-69. [PMID: 20804530]
- Front Immunol. 2022 Sep 29; 13:945994. [PMID: 36263028]
- Vox Sang. 2014 Feb; 106(2):93-102. doi: 10.1111/vox.12085. Epub 2013 Sep 16. [PMID: 24102564]